Novartis Pharmaceuticals Corp. v. Apotex Inc.

Case Overview and Background

Parties, accused product, and patent. This is a Hatch-Waxman/ANDA action brought by Novartis Pharmaceuticals Corp., the U.S. operating subsidiary of Swiss innovator Novartis AG (a practicing entity — Stanford's NPE Litigation Database classifies the plaintiff as a "product company"), against Apotex Inc. and its U.S. subsidiary Apotex Corp., Canadian-headquartered generic manufacturers. Novartis sued on July 13, 2018, alleging that Apotex's filing of ANDA No. 207993 — seeking FDA approval to market generic fingolimod 0.5 mg capsules, a copy of Novartis's blockbuster multiple-sclerosis drug Gilenya® — infringed U.S. Patent No. 9,187,405 under 35 U.S.C. § 271(e)(2). The '405 patent, "S1P receptor modulators for treating relapsing-remitting multiple sclerosis," is a dosing-regimen method patent: claim 1 covers treating relapsing-remitting MS (RRMS) by orally administering fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol) at a daily dosage of 0.5 mg "absent an immediately preceding loading dose regimen." That negative limitation (no loading dose) became the central validity battleground. The complaint lists the patent's expiry as June 25, 2027 (Novartis later cited December 25, 2027 including pediatric exclusivity); the '405 is listed in the Orange Book for Gilenya® (CourtListener docket 7432325, D.I. 1; Google Patents US9187405B2; pharsight.greyb.com).

Procedural posture and venue. The case was assigned to Judge Leonard P. Stark (later Chief Judge, and now a Federal Circuit judge) in the District of Delaware — the dominant venue for ANDA litigation — as one of four same-day coordinated suits over the same patent: 18-cv-01038 (Apotex), 18-cv-01039 (Teva), 18-cv-01040 (Sun Pharma), and 18-cv-01043 (Accord/HEC), consolidated for all pretrial purposes on October 25, 2018 with 18-cv-1043-LPS as lead case (D.I. 48; lead-case D.I. 237). Apotex moved to stay (D.I. 11) pending its Federal Circuit appeal of the PTAB's final written decision in IPR2017-00854, an inter partes review Apotex had filed in February 2017 challenging the '405; the case was stayed on November 14, 2018 under a stipulation (lead-case D.I. 237) in which Apotex conceded the ANDA filing was an act of infringement and agreed to be bound by the consolidated action's validity adjudication, and the stay motions were later denied as moot on June 8, 2020 (D.I. 54). The lead case proceeded to a bench trial — the district court found the '405 valid and infringed and entered a permanent injunction against HEC through the patent's expiry (Aug. 2020 decision; Novartis press release, Jan. 4, 2022) — and was appealed as Novartis Pharms. Corp. v. Accord Healthcare, Inc., No. 2021-1070 (Fed. Cir.). This Apotex action itself, however, never reached a merits decision: it was terminated on April 20, 2022, with case records (DrugPatentWatch; Unified Patents portal; CourtListener IDB) and the case metadata reflecting resolution by confidential settlement — consistent with Novartis's disclosed confidential settlement/licensing agreements with multiple ANDA filers permitting generic entry on undisclosed dates before the December 2027 patent expiry (Novartis PR, Jan. 4, 2022; BioPharma Dive, Oct. 2022).

Why the case is notable. The litigation sits at the center of the Gilenya exclusivity wars: Gilenya was the first oral MS therapy and one of Novartis's top sellers (~$2.8–3 billion/year), and the '405 dosing-regimen claims were the last line of defense after the PTAB and Federal Circuit had invalidated the companion composition patent (U.S. 8,324,283) in earlier IPRs — which is precisely why Novartis filed this wave of ANDA suits within days of the PTAB's July 11, 2018 final written decision in IPR2017-00854 upholding all claims of the '405 (PTAB Litigation Blog/Jones Day, July 2018; RPX Insight). Its lasting significance is jurisprudential: the consolidated litigation produced the landmark Federal Circuit enunciation of the written-description standard for negative claim limitations. In Novartis v. Accord, a January 3, 2022 panel (Linn, O'Malley; Moore dissenting) affirmed the district court, but after Judge O'Malley's retirement, the court granted a rare panel rehearing and, on June 21, 2022, reversed in a 2–1 decision (Moore, Hughes; Linn dissenting), holding that the "absent an immediately preceding loading dose regimen" limitation lacked 35 U.S.C. § 112(a) support because "[s]ilence is generally not disclosure" — the specification nowhere discussed loading doses, and the limitation had been added during prosecution to overcome prior art (2022 WL 2204163; IPWatchdog, June 21, 2022; A&O Shearman summary). Chief Justice Roberts subsequently stayed the Federal Circuit's mandate pending Novartis's certiorari petition (BioPharma Dive, Oct. 2022); the ultimate Supreme Court disposition was not confirmed in the sources I reviewed, and by then this Apotex action had already resolved. The case is thus a textbook example of (1) the interplay between IPR and ANDA litigation, (2) the value of later-expiring dosing-regimen patents after composition patents fall, and (3) confidential settlement-and-license resolutions that let generics enter before patent expiry — here, generic competition arrived around 2024 under those settlements, per Novartis's own analyst guidance (BioPharma Dive).

Key sources: CourtListener docket 7432325 (D.I. 1, 11, 48, 54; lead-case D.I. 237 stipulation, storage.courtlistener.com/recap/gov.uscourts.ded.65791/gov.uscourts.ded.65791.237.0_1.pdf); Unified Patents portal 1:18-cv-01038; DrugPatentWatch; Stanford NPE Litigation Database (case 205896; patent 9187405); PTAB Litigation Blog (IPR2017-00854, Paper 109, July 11, 2018); RPX Insight IPR2017-00854; Novartis Pharms. Corp. v. Accord Healthcare, Inc., No. 2021-1070 (Fed. Cir. Jan. 3, 2022, and June 21, 2022); IPWatchdog (June 21, 2022); Novartis PR (Jan. 4, 2022); BioPharma Dive (Oct. 2022).

I'll research this case thoroughly, starting with the docket and parallel proceedings.

I have good initial leads. Now let me dig into the parallel IPR proceedings and the Federal Circuit appeals, plus the related lead case.

I now have the core structure. Let me get the full docket details for the Apotex case and the Federal Circuit IPR appeal dismissal.

Novartis Pharmaceuticals Corp. v. Apotex Inc., No. 1:18-cv-01038-LPS (D. Del.)

Case in brief

An ANDA/Hatch-Waxman action under 35 U.S.C. § 271(e)(2), filed 2018-07-13, in which Novartis accused Apotex Inc. and Apotex Corp. of infringing U.S. Patent No. 9,187,405 ("S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis," issued 2015-11-17) based on Apotex ANDA No. 207993 for fingolimod 0.5 mg capsules (generic Gilenya®). The '405 patent claims a method of treating relapsing-remitting MS with 0.5 mg fingolimod daily "absent an immediately preceding loading dose regimen." Per the CourtListener docket's supplemental ANDA information, patentee notice was recorded as received 2016-01-22 and patent expiration as 2027-06-25 (drugpatentwatch lists pediatric-adjusted expiry through Dec. 2027). The case was assigned to Judge Leonard P. Stark and was one of four associated Novartis fingolimod cases (1:18-cv-01038 [Apotex], -01039, -01040, and -01043 [lead case, Novartis v. Accord Healthcare Inc.]); the parties later consolidated discovery and stayed the Apotex action in favor of lead case 18-1043. It closed by settlement on 2022-04-20, consistent with the case metadata's characterization ("resolved by confidential settlement licensing entry before patent expiry").

---

1. Filing & initial pleadings

• 2018-07-13 — Complaint filed (D.I. 1) against Apotex Inc. and Apotex Corp.; summons issued the same day; Patent/Trademark Report to the Commissioner for the '405 patent filed. Case assigned to Judge Leonard P. Stark (LPS) on 2018-07-18 and associated with the four related LPS cases. (CourtListener docket 7432325; Unicourt; Unified Patents portal.)
• 2018-07-18 — Apotex Corp. served (answer due 2018-08-08).
• 2018-07-23/24 — Novartis' pro hac vice motion for Gibson Dunn attorneys Jane M. Love, Robert Trenchard, Paul Torchia, and Andrew Blythe filed and granted.
• 2018-08-08 — Answer, defenses, and counterclaim by Apotex Inc. and Apotex Corp. (D.I. 9; counsel David Ellis Moore, Bindu Palapura of McCarter & English; Wilson Sonsini later admitted pro hac vice on 2018-09-14 — Tung-On Kong, Dennis D. Gregory, Mary Procaccio-Flowers, Diyang Liu). The docket confirms counterclaims were asserted; the stay stipulation later recites that "Apotex challenges the validity and enforceability of the '405 patent before this Court," so the counterclaims were in substance invalidity/unenforceability (and standard ANDA non-infringement) declaratory claims, though I could not confirm the exact counterclaim text from public sources.
• 2018-08-29 — Novartis' answer to Apotex's counterclaim (D.I. 16).
• Early discovery exchanged pre-stay: Novartis' initial disclosures of accused products/asserted patents (2018-08-31, D.I. 18) and first sets of RFPs and interrogatories (2018-09-04, D.I. 20-21).

2. Pre-trial motions of substance

• ~2018-08-13/14 — Apotex's Motion to Stay Proceedings Pending the Appeal of an IPR Decision on the Sole Patent in Suit (D.I. 11), with opening brief (D.I. 12). This was premised on the PTAB's 2018-07-11 Final Written Decision in IPR2017-00854 (claims 1-6 upheld) and Apotex's Federal Circuit appeal of that decision (Fed. Cir. No. 2018-2209, notice of appeal filed 2018-07-27).
• 2018-08-22 — Novartis' opposition (D.I. 13) with the Trenchard declaration (D.I. 14); Apotex reply (D.I. 17) on 2018-08-29.
• 2018-09-06/07 — Motion practice over sur-replies (Novartis D.I. 24; Apotex unopposed sur-sur-reply D.I. 25; order D.I. 26 on 2018-09-07). The Court set oral argument on the stay motion for 2018-11-19 (D.I. 23, 2018-09-06).
• 2018-11-05/14 — Instead of a ruling, the parties filed a Stipulation and Proposed Order to Stay (filed in lead case 18-1043 as D.I. 237). Key terms: Apotex did not contest that filing ANDA No. 207993 constitutes an act of infringement under § 271(e)(2); all claims/defenses/counterclaims between Novartis and Apotex were stayed; Apotex agreed to be bound by the merits adjudication of validity/enforceability of the '405 patent in the consolidated action (18-1043) and to refrain from marketing its ANDA product unless/until the patent was found invalid or unenforceable in a final decision; no willful-infringement/§ 285 exceptional-case findings were to apply as between Novartis and Apotex. The Court stayed the case on 2018-11-14 and cancelled the 2018-11-19 hearing (D.I. 49). (Stipulation text at CourtListener D.I. 237 in 18-1043.)
• 2018-10-25 — Scheduling Order, Protective Order, and ESI Order entered (oral order D.I. 48): the Court imposed time limits on Rule 30(b)(6) deposition hours, allowed longer inventor depositions and longer expert depositions for dual infringement/validity experts, and included a "patent-claim-drafting bar" restricting receiving counsel from drafting/amending patent claims — a notable protective-order ruling balancing cross-defendant information sharing.
• 2020-06-08 — Oral order: the outstanding motions to stay (D.I. 11 and D.I. 45) were denied as moot (CourtListener docket feed entry #54). I could not confirm from public sources who filed D.I. 45 or its exact content; it was evidently a later-filed stay-related motion rendered moot (by then the case was already stayed by stipulation and Apotex's IPR appeal had been dismissed).

There were no motions to dismiss, no transfer motion, and no summary-judgment motion in the Apotex case — the case was stayed within months of filing and never returned to active merits litigation.

3. Claim construction (Markman)

No Markman proceedings occurred in 1:18-cv-01038. The case was stayed on 2018-11-14, before any claim-construction schedule. Claim construction on the '405 patent did occur in the parallel forums:

• In IPR2017-00854, the PTAB construed terms (e.g., preamble limiting-effect, "daily dosage of 0.5 mg") under the broadest reasonable interpretation standard in its final written decision (2018-07-11, Paper 109).
• In the consolidated lead case (18-1043), the district court addressed construction issues in the context of the 2020 bench trial (e.g., the negative limitation "absent an immediately preceding loading dose regimen").

4. Discovery milestones with strategic significance

• 2018-08/09 — Initial disclosures and Novartis' first sets of common and Apotex-specific RFPs/interrogatories (D.I. 18, 20, 21) — the only merits discovery served before the stay.
• 2018-10-16 — Discovery/scheduling teleconference before Judge Stark (court reporter B. Gaffigan) after the parties reported a discovery impasse; the resulting 2018-10-25 orders (D.I. 48) resolved deposition-hour limits, inventor-deposition length, and the protective order's claim-drafting bar.
• 2018-11-14 — Stay entered; all further merits discovery in the Apotex case was frozen. Post-stay docket activity was ministerial: a sealed/redacted transcript of a 2018-12-21 telephone conference before Judge Stark (D.I. 51-52), HEC's consolidated invalidity contentions re the '405 patent (2018-12-13, D.I. 50, filed on the associated docket due to consolidation), and counsel-withdrawal notices (2019-10-17).
• Strategically significant discovery occurred in the parallel IPR: on 2018-02-21 the PTAB granted in part Apotex's request for additional discovery of the Phase III clinical-trial protocol sections Novartis provided to the FDA justifying the 0.5 mg dose (IPR2017-00854, Paper 52) — evidence central to the obviousness fight over the claimed dose.

5. Trial events, verdict, and post-trial motions

No trial occurred in the Apotex case itself. The operative merits adjudication was the bench trial in the consolidated lead case, 1:18-cv-01043 (which by stipulation bound Apotex):

• 2020-03-02 to 03-05 — Four-day bench trial before Judge Kent A. Jordan (Third Circuit judge sitting by designation) in Novartis v. Accord Healthcare Inc. (18-1043), involving HEC Pharm as the remaining active challenger.
• 2020-08-10 — Findings of Fact & Conclusions of Law (D.I. 769): HEC liable for contributory and induced infringement; the '405 patent not invalid (written description adequate for the no-loading-dose negative limitation and the 0.5 mg dose; no anticipation by the Kappos 2006 abstract).
• 2020-09-11 — Final judgment entered for Novartis in the lead case (D.I. 780); consent judgments and injunctions were later entered against settling defendants (e.g., Mylan, 2020-10-26 proposed consent judgment, D.I. 803; Aurobindo final judgment 2021-01-21, D.I. 817).
• 2022-01-03 — Federal Circuit panel decision in Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc., No. 2021-1070 (initial opinion at 38 F.4th 1012): affirmed the district court, holding the written description finding not clearly erroneous (2-1; Judge Moore dissenting, arguing "silence is not disclosure").
• 2022-06-21 — On panel rehearing, the Federal Circuit granted HEC's petition, vacated its prior decision, and reversed, holding claims 1-6 of the '405 patent invalid for inadequate written description of the negative limitation "absent an immediately preceding loading dose regimen" (No. 2021-1070, June 21, 2022 opinion). Judge Moore's position prevailed.
• 2022-10 onward — Novartis sought Supreme Court relief (emergency application to stay the mandate, 22A272; certiorari petition). HEC's opposition submissions (e.g., the Hofmann rebuttal declaration of 2022-10-05) argued no irreparable harm from the mandate issuing and generic launch. The Supreme Court declined to intervene; the mandate issued and the '405 patent claims were invalidated.
• 2024-08-05 — Post-mandate fallout in the lead case: HEC appealed the district court's August 2024 memorandum opinion/order (D.I. 899/900) to the Federal Circuit (No. 24-2194) and the Third Circuit, reflecting continued disputes (fees/contempt/termination issues) after the invalidation.

6. Settlement, dismissal, judgment, or appeal — final disposition of the Apotex case

• The Apotex action remained stayed from 2018-11-14 through the lead-case trial, judgment, and the initial Federal Circuit affirmance.
• 2022-04-01 — Joint status report filed on the associated docket (lead case D.I. 818, referencing orders in 18-1040 and 18-1038), signaling the parties were winding the stayed cases down.
• 2022-04-20 — The case was terminated (final civil docket 04-20-2022; DrugPatentWatch lists "Date Terminated 2022-04-20"). Public sources do not show the specific closing instrument (stipulation of dismissal vs. consent judgment), but the metadata and surrounding events indicate a confidential settlement and license of Apotex's fingolimod ANDA entry — reached while Novartis was still winning (post-January 2022 affirmance, before the June 2022 reversal), which explains the timing. The docket also reflects termination of the ADR referral on 2022-04-11 (per the Court's Standing Order 2022-2).
• The Federal Circuit's June 2022 invalidation of the '405 patent therefore post-dated and did not affect the Apotex settlement; it did, however, eliminate the patent-based barrier to generic fingolimod entry for all filers, including Apotex.

7. Parallel PTAB proceedings (IPR2017-00854 and joined cases)

• 2017-02-03 — Apotex Inc. and Apotex Corp. filed IPR2017-00854 challenging claims 1-6 of the '405 patent on § 102/§ 103 grounds (three grounds; Apotex was lead petitioner).
• 2017 (mid-year) — Three substantively identical petitions with joinder requests were filed and granted joinder into IPR2017-00854: IPR2017-01550 (Argentum Pharmaceuticals), IPR2017-01946 (Actavis Elizabeth/Teva), and IPR2017-01929 (Sun Pharma entities). Apotex remained lead petitioner.
• 2018-02-21 — PTAB granted in part Apotex's additional-discovery request for FDA-facing Phase III protocol materials justifying the 0.5 mg dose (Paper 52).
• 2018-07-11 — Final Written Decision (Paper 109): claims 1-6 not shown unpatentable on any ground (panel: Judges Kaiser, Pollock, Sawert); Novartis' contingent motion to amend was denied. The IPR certificate confirming patentability of claims 1-6 issued 2020-02-10.
• 2018-07-27 — Apotex appealed the FWD to the Federal Circuit (No. 2018-2209).
• 2019-2020 — The parallel appeals unraveled: Teva/Actavis (No. 18-2260) and Sun (No. 18-2230) dismissed after settlements before argument; Apotex settled after argument and its appeal (No. 18-2209) was dismissed; Argentum's appeal (No. 18-2273) was dismissed on 2020-01-28 for lack of Article III standing (Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corp., Fed. Cir. 2020).
• Effect on the litigation: The IPR success (claims upheld) drove Apotex's district-court stay motion and the parties' 2018 stipulation staying the Apotex case pending the IPR appeal. Apotex's mid-2019/early-2020 settlement of the IPR appeal coincided with its licensing settlement with Novartis. The § 315(e) estoppel from the IPR limited Apotex's re-litigation of the IPR grounds, but the district-court invalidity case (in the lead action) proceeded on different theories — ultimately succeeding on written description at the Federal Circuit in June 2022, a result reached after Apotex had already settled.

---

Bottom line

The Apotex case was procedurally short-lived: filed 2018-07-13, answered with counterclaims 2018-08-08, stayed by stipulation 2018-11-14 in favor of the consolidated lead case (18-1043), and terminated 2022-04-20 by confidential settlement — never reaching Markman, summary judgment, or trial. The substantive fight over the '405 patent played out in the PTAB (IPR2017-00854, claims upheld 2018-07-11), in the lead-case bench trial (Novartis win, 2020), and on appeal (initial affirmance Jan. 2022, then reversal on rehearing June 2022 invalidating the claims for inadequate written description). Apotex's exit came via settlement while Novartis still held the winning hand; the subsequent invalidation mooted the patent barrier for everyone. A new, separate Novartis v. Apotex ANDA suit on different fingolimod patents (1:25-cv-01330, filed 2025-10-30) shows the parties remain adversaries on later-filed patents.

Caveats: I could not verify from public sources the exact text of Apotex's counterclaims, the identity/content of D.I. 45, or the specific closing document filed on 2022-04-20; those points are flagged above. The recorded notice date (2016-01-22) comes from the CourtListener supplemental ANDA information and is otherwise unexplained given the 2018 filing date.

I'll research press coverage of this case from multiple angles.

Good context. Now let me search for press and trade coverage.

Now let me search for coverage specific to the Apotex case and the 2018 filing wave.

Sources

• Novartis Pharmaceuticals Corporation v. Apotex Inc., 1:26-cv-00141 - CourtListener.com - 🚀 Limited-time offer
• IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
• APPENDIX TABLE OF CONTENTS
• Novartis Pharmaceuticals Corporation v. Apotex Inc. et al
• Novartis Pharmaceuticals Corporation v. Apotex Inc. et al (1:26-cv-00141), Delaware District Court
• United States Court of Appeals for the Federal Circuit
• Case 1:18-cv-01043-KAJ Document 769 Filed 08/10/20 Page 1 of 37 PagelD #: 38595
• PTAB Upholds GILENYA™ Method of Treatment Patent, Prompting New ANDA Litigation - PTAB Litigation Blog
• PTAB Upholds GILENYA™ Method of Treatment Patent, Prompting New ANDA Litigation - Register now for your free, tailored, daily legal newsfeed service.
• IN THE UNITED STATES DISTRICT COURT
• UNITED STATES PATENT AND TRADEMARK OFFICE
• Answer: Apotex admits that Novartis Pharmaceutical Corporation is listed in publically available documents as the holder of New ...

Plaintiff's Counsel of Record — Novartis Pharmaceuticals Corp. v. Apotex Inc., 1:18-cv-01038 (D. Del.)

Based on the docket for this ANDA/Hatch-Waxman action (filed July 13, 2018; assigned to Judge Leonard P. Stark; terminated by settlement April 20, 2022), the plaintiff-side team consisted of Delaware local counsel from McCarter & English LLP plus substantive lead counsel admitted pro hac vice from Gibson, Dunn & Crutcher LLP (New York). The case was litigated in a consolidated group with 1:18-cv-01039, 1:18-cv-01040, and lead case 1:18-cv-01043 (Novartis v. Accord Healthcare), all involving the '405 patent (Gilenya®/fingolimod 0.5 mg).

Local (Delaware) counsel — McCarter & English LLP, Wilmington, DE

Lead / pro hac vice counsel — Gibson, Dunn & Crutcher LLP, New York, NY

Admitted pro hac vice by order dated July 24, 2018 (D.I. 6 motion for PHV appearance of Jane M. Love, Robert Trenchard, Paul E. Torchia, and Andrew P. Blythe; SO ORDERED by Judge Stark on 7/24/18). The related-case complaint signature blocks confirm the Gibson Dunn affiliation: "Jane M. Love, Ph.D., Robert Trenchard, Paul E. Torchia, GIBSON, DUNN & CRUTCHER LLP, 200 Park Avenue, New York, NY 10166."

In-house counsel

None appeared of record. No Novartis in-house attorney is listed on the CM/ECF docket or the UniCourt/PACER attorney rosters for this case; Novartis Pharmaceuticals Corp.'s Rule 7.1 disclosure (identifying parent Novartis AG) was filed by outside counsel. If in-house attorneys (e.g., Novartis's IP legal group) managed the matter, they did not enter appearances in the District of Delaware.

Procedural context worth noting

• The docket reflects that the case was stayed on November 14, 2018 per stipulation in the lead case (D.I. 49, canceling the Nov. 19, 2018 stay hearing) while the IPR decision on the '405 patent was on appeal; the stay motions (D.I. 11, 45) were denied as moot on June 8, 2020 (D.I. 54).
• The consolidated Accord lead case later produced the Federal Circuit decision that invalidated the '405 patent after rehearing, with certiorari denied April 17, 2023 — but the Apotex-specific docket (1:18-cv-01038) closed April 20, 2022 via confidential settlement/licensing, consistent with the case metadata.

Sources: CourtListener docket 7432325 (D.I. 6 PHV motion and SO ORDERED, D.I. 49, D.I. 54); UniCourt case page 807448 (attorney roster); Unified Patents portal (PHV notices); Gibson Dunn attorney profiles (Love, Trenchard, Torchia); PTAB filings in IPR2017-01550 (Trenchard declaration re '405 patent); complaint signature block in related case 1:18-cv-01040 (paragraphfour.com); Justia/Federal Circuit docket for lead case 1:18-cv-01043. Where a specific fact (e.g., Blythe's exact firm) is not independently verified, I've flagged it rather than asserting it as certain.

Counsel of Record — Defendants Apotex Inc. and Apotex Corp.

Based on the docket record for 1:18-cv-01038-LPS (CourtListener docket 7432325; UniCourt case 807448; Patexia service records), Apotex's defense was a two-tier team: Delaware local counsel from Potter Anderson & Corroon LLP and pro hac vice lead counsel from Wilson Sonsini Goodrich & Rosati (WSGR).

Delaware local counsel — Potter Anderson & Corroon LLP (Wilmington, DE)

1. David Ellis Moore — Lead local counsel / Attorney to be Noticed.

   • Firm: Potter Anderson & Corroon LLP, 1313 N. Market St., Hercules Plaza, 6th Flr., Wilmington, DE 19899.
   • UniCourt lists him (with Palapura) as the Defendant and Counter Claimant attorney of record for Apotex; his signature appears on Apotex stay filings in this case (e.g., sur-sur-reply brief in support of the motion to stay, D. Del. filings entered by Palapura/Moore). He is a long-standing Delaware IP litigator who routinely serves as local counsel for generic pharma defendants in Hatch-Waxman/ANDA suits in D. Del. (e.g., Mylan, Alembic, AMD matters in the same court).

2. Bindu Ann George Palapura — Local counsel / Attorney to be Noticed.

   • Firm: Potter Anderson & Corroon LLP, same Wilmington office (302-984-6000; bpalapura@potteranderson.com).
   • Listed by UniCourt as Apotex's counsel of record alongside Moore; she signed the Apotex stay briefing papers (UniCourt docket entries referencing "Sur-Sur-Reply Brief in Support of Motion to Stay" and "Exhibit A–C" filed by Palapura). Seasoned Delaware IP litigator with a deep ANDA-defense docket.

Pro hac vice (lead) counsel — Wilson Sonsini Goodrich & Rosati

Granted by Judge Stark on September 14, 2018, via D.I. 19 (motion filed by Apotex Inc. and Apotex Corp.; "SO ORDERED, re [19] MOTION for Pro Hac Vice Appearance of Attorney Tung-On Kong, Dennis D. Gregory, Mary Procaccio-Flowers, and Diyang Liu of Wilson Sonsini Goodrich & Rosati"):

1. Tung-On Kong — Pro hac vice counsel (WSGR).

   • Lead figure among the WSGR quartet; WSGR was the same firm that represented Apotex as lead petitioner in the parallel IPR2017-00854 (where WSGR's Steven W. Parmelee, Michael T. Rosato, and Jad A. Mills signed the IPR petition). Kong is a WSGR IP litigator focused on patent litigation and post-grant proceedings.

2. Dennis D. Gregory — Pro hac vice counsel (WSGR).

3. Mary Procaccio-Flowers — Pro hac vice counsel (WSGR).

   • Note: The docket reflects a later "NOTICE requesting Clerk to remove Mary Procaccio-Flowers of Wilson Sonsini Goodrich & Rosati as co-counsel" (CourtListener docket feed, entry ~53), so she had withdrawn from the case before termination.

4. Diyang Liu — Pro hac vice counsel (WSGR).

Not counsel of record for Apotex (avoid confusion)

• John C. Phillips Jr. (whose name appears on joint "Defendants' Response" discovery letters in the consolidated docket) and Kenneth Dorsney (Morris James, on Bionpharma/Hetero/Prinston filings) represented other defendants in the consolidated actions (18-cv-1043 lead case group), not Apotex specifically — Apotex's own filings in this action bear the Potter Anderson and WSGR names above.
• The WSGR attorneys on the IPR petition (Parmelee, Rosato, Mills) were PTAB counsel for Apotex in IPR2017-00854, not counsel of record in this district court action, though they are the same firm and litigation team.

Caveats

• No Apotex in-house counsel appeared as counsel of record in the public docket entries reviewed; none was identified.
• Specific WSGR office locations for Kong, Gregory, Procaccio-Flowers, and Liu were not confirmed in the sources reviewed (WSGR's IP practice is headquartered in Palo Alto with multiple offices), so I have not assigned individual offices.
• The case was stayed as to Apotex in November 2018 and later dismissed by stipulation on April 20, 2022 (D.I. 57), so there was no merits appearance beyond discovery/stay-stage filings; the counsel list above reflects the appearances made through that procedural posture.

Key sources: CourtListener docket 7432325 (D.I. 19, 53, 57; feed entries); UniCourt case 807448 (attorney listings); Patexia litigation service (D.I. 19 pro hac vice order text, 9/14/18); IPR2017-00854 petition (WSGR, Feb. 3, 2017); lead-case stipulation D.I. 237 (storage.courtlistener.com).